“Genome Center” posted the second case of omicron “BA.2.75.2” in Thailand as “female”.

On September 20, 65, reporters reported that the Facebook page of the Center for Medical Genomics posted a message saying ..

According to the global COVID genetic code “GISAID”, the second case of omicron subspecies “BA.2.75.2” in Thailand was found to be “female”.

Omicron BA.2.75.2 :- Data from the UK research team They found that immune evasion performance was 5 times better than BA.5 and 4 times better than BA.4.6, resisting most antibodies used to treat COVID- 19, including “Evusheld”.

There is no need to “panic”, BA.2.75.2 found, only “464 cases” in the global database of COVID-19 “GISAID” (in Thailand, two cases) can progress from COVID-19, but must be aware that the card does not fall in order not to let BA.2.75.2 have a chance to replace BA.4.6 and BA.5

geographical distribution

https://cov-spectrum.org/…/AllSamples/Past6M/variants…&

India

143

0.489%

United States

112

0.014%

Singapore

43

0.500%

Australia

20

0.032%

South Korea

20

0.054%

Austria

19

0.027%

Japan

18

0.013%

Israel

13

0.019%

England

13

0.003%

Canada

13

0.014%

Germany

8

0.003%

The Netherlands

7

0.026%

Denmark

6

0.004%

New Zealand

5

0.042%

Belgium

4

0.011%

Ireland

3

0.012%

France

3

0.002%

Spain

2

0.006%

Slovenia

2

0.020%

================

Thailand

2 cases

Found in 0.030% new infected

================

Switzerland

2

0.014%

Sweden

2

0.008%

Luxembourg

1

0.006%

Hong Kong

1

0.030%

Chile

1

0.009%

Nepal

1

0.304%

Update 19/9/22 at 23.30

The latest data from a research team in the European Union (European Union: EU) on 16/Sep/22, reported in an academic journal shows laboratory data that Omicron BA.2.75.2 and BA.4.6 (Image 1) can avoid “Single antibody drugs” and “combined antibody drugs” as well as “Evuheld/Evusheld”, a combination of the antibody ziggavimab/cilgavimab and tiggevimab/tixagevimab”, make people infected with such strains Omicron 2 are more difficult to handle. due to resistance. Only a few synthetic antibodies, such as “bebtelovimab/bebtelovimab”, were also able to inhibit omicron proliferation of BA.2.75.2 and BA.4.6 (Figure 2).

Data from the UK research team. The immune evasion performance of Omicron BA.2.75.2 was 5 times better than BA.5 and 4 times better than BA.4.6 (Figure 2.1).

https://www.biorxiv.org/content/10.1101/2022.09.16.508299v1

These data have raised concerns for experts that Omicron BA.2.75.2 and BA.4.6 may have evaded physical immunity to outbreaks in populations. In particular, countries in the Northern Hemisphere are approaching winter where people gather in shelters to avoid the cold weather. causing airborne diseases and close contact more contact

The conjugated antibody drug “Evuscheld” has just been approved by the EU for the treatment of COVID-19. Because it can prevent the spread of BA.1, BA.2, BA.4/BA.5, and BA.2.75 in the patient’s body well to some extent. At the time of approval, there was no information on “Mutation Omicron BA.4 to BA.4.6” and “Mutation Omicron BA.2.75 to BA.2.75.2” resistant to Ewucheld (Figure 3).

Immune evasion performance was 5 times better than BA.5 and 4 times better than BA.4.6 (Figure 3.1).

https://www.biorxiv.org/…/10.1101/2022.07.14.500041v1.full

The use of “conjugated antibody drugs” in Thailand is indicated for the treatment of COVID-19 in patients aged 12 years and older with “mild to moderate symptoms” who do not require any high-flow oxygen. or a vulnerable group of patients at high risk of the disease progressing to severe symptoms From clinical research, it was found that combined antibody drug therapy can reduce the amount of virus in the bloodstream and prevent infection of the body. including reducing the length of hospital stay

———————————-

Medical Genome Center Recognizing the need to quickly detect different types of omicron within 24-48 hours whether delta or omicron subspecies BA.2, BA.4, BA.4.6, BA .5, BA.2.12.1, BA .2.75, BA.2.75. 1, BA.2.75.2, etc. due to the treatment of COVID-19 It began to have the characteristics of precision medicine and goal (precision medicine) more and more. Unlike the early treatment of the 2019 epidemic where all patients received the same treatment. (One size fits all) because medical supplies such as vaccines (main needles and booster needles), antivirals and ready-made antibodies used to treat COVID-19 are currently found to be effective in preventing or treating all strains of the 2019 coronavirus .different For example, Omicron left BA.4.6 and BA.2.75.2 synthetic antibody drugs. “Bebtelovimab/bebtelovimab” was also able to inhibit omicron proliferation of BA.4.6 and BA.2.75.2.

———————————-

The second generation vaccine that can protect against the coronavirus-19 that currently has a different mutation from the original virus or a third generation vaccine that can prevent all mutated viruses from spreading in the future (Universal coronavirus vaccine) is needed.

———————————-

Omicron “BA.2.75.2”, which is covid-19 “Generation 3”, the Genome Center recently reported one case in Thailand. Read the details at https://www.facebook.com/CMGrama/posts/pfbid05TqwuDQLJoiNXQBgmPdR1PTGzz3mcxuHrSbSMcR58hDYSNSKxLNaPYnYKyV7TxZQl

According to the latest global COVID-19 genetic code information “GISAID”, the second case of Omicron subspecies “BA.2.75.2” was detected in Thailand as a “female” sample collected on September 18, 2022 from the hospital. in Bangkok (Photo 0)

———————————-

while BA.4.6 was first detected in January 2022 in South Africa. although it is not found in Thailand But, according to the US Centers for Disease Control and Prevention (US CDC), Omicron BA.4 has mutated to BA.4.6 and is slowly replacing BA.5.10 .3 of the new cases in the United States is omicron BA.4.6 (Figure 4) and has begun to spread to many places around the world, including the UK, 3.3 percent of the new cases detected.

Omicron BA.4.6 is mutated from BA.4 with about 85 different mutations than the original (Wuhan) virus (Figure 1).

Severity, Infection and Immunity Avoid Omicron BA.4.6

Fortunately, most omicron infections do not have serious illnesses. There is a lower rate of infection and death than previous generations. One factor may be that most people in the world are vaccinated and infected naturally, but Omicron BA.4.6 has a unique ability to transmit faster than Omicron BA.5 has an advantage in growth-spread (relative growth advantage) about 19 % compared to the BA.5 strain which is currently common worldwide (Figure 5).

———————————-

Omicron subspecies BA.2.75.2 with additional mutations from BA.2.75 on three spikes, R346T, F486S and D1199N.

Omicron subspecies BA.4.6 has a thorn as well as only one BA.4 mutation, R346T.

Omicron subspecies BA.2.75.2 with 13 additional mutations from BA.5 on thorns.

Omicron BA.2.75.2 has a relative growth advantage of approximately 71% compared to BA.5 strains currently infecting the world (Figure 7).

As a result, B A.2.75.2 and ฺBA.4.6 currently have the fastest growth and spread (Figure 6, 7).

https://theconversation.com/another-new-covid-variant-is…

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.